View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsPharma Mar 配当と自社株買い配当金 基準チェック /26Pharma Mar配当を支払う会社であり、現在の利回りは1.96%で、収益によって十分にカバーされています。主要情報2.0%配当利回り-1.2%バイバック利回り総株主利回り0.8%将来の配当利回り2.0%配当成長10.8%次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向24%最近の配当と自社株買いの更新Upcoming Dividend • Jul 06Upcoming dividend of €0.53 per shareEligible shareholders must have bought the stock before 13 July 2022. Payment date: 15 July 2022. Payout ratio is a comfortable 13% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of Mexican dividend payers (6.1%). Lower than average of industry peers (2.4%).すべての更新を表示Recent updatesお知らせ • Feb 10Pharma Mar, S.A. to Report Fiscal Year 2024 Results on Feb 28, 2025Pharma Mar, S.A. announced that they will report fiscal year 2024 results on Feb 28, 2025お知らせ • Oct 22Pharma Mar, S.A. to Report Q3, 2024 Results on Oct 29, 2024Pharma Mar, S.A. announced that they will report Q3, 2024 results on Oct 29, 2024お知らせ • Oct 16Pharmamar Announces Positive and Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung CancerPharmaMar announced positive top-line results from the Phase 3 clinical trial evaluating Zepzelca® (lurbinectedin) in combination with the PD-L1 inhibitor atezolizumab (Tecentriq®) compared to atezolizumab alone when administered as a maintenance treatment for adults with extensive-stage Small Cell Lung Cancer (ES-SCLC) following induction therapy with carboplatin, etoposide and atezolizumab. The combination of lurbinectedin and atezolizumab demonstrated a statistically significant improvement in the primary endpoints of overall survival (OS) and progression-free survival (PFS), as assessed by an independent review facility (IRF), compared to treatment with atezolizumab alone. The combination was generally well-tolerated. The preliminary safety data in the ongoing trial is consistent with the known safety profiles of lurbinectedin and atezolizumab with no new safety signals observed in the combination arm. Jazz and Roche plan to submit these data for presentation at a future medical meeting. PharmaMar will submit a marketing authorisation application (MAA) to the EMA in the first half of 2025 to request regulatory approval in the European Union (EU). Lurbinectedin is available for use in 16 territories around the world.お知らせ • Jul 27Pharma Mar, S.A. to Report First Half, 2024 Results on Jul 30, 2024Pharma Mar, S.A. announced that they will report first half, 2024 results on Jul 30, 2024お知らせ • Jun 05Pharma Mar Presents Encouraging Results At ASCO for Small Cell Lung CancerPharmaMar presented data from a Phase II trial evaluating PharmaMar's lurbinectedin in combination with irinotecan in patients with relapsed Small Cell Lung Cancer (SCLC) after prior platinum-based treatment at the American Society of Clinical Oncology (ASCO) meeting, which took place from 31st May to 4th June in Chicago, United States. PharmaMar has a unique technological platform: the sea. Since 1986, it has been researching the marine ecosystem to discover innovative therapeutic alternatives for serious diseases, such as cancer, for this purpose it has invested more than EUR 1 billion since its foundation. After reaching patients all over the world and changing the paradigm of sarcoma treatment, in addition to having three therapies commercially available, it is currently working to improve the lives of patients with Small Cell Lung Cancer, the most aggressive type of lung cancer. Regarding this disease, the results presented by the company at ASCO show that the combination of its drug for this pathology, Zepzelca® (lurbinectedin), in combination with irinotecan produces a synergy that enhances the activity of lurbinectedin, resulting in high and durable response rates in populations that are sensitive, with a chemotherapy-free interval greater than 90 days (CTFI> 90 days), and platinum-resistant with a chemotherapy-free interval of less than 90 days (CTF< 90 days). Particularly encouraging are the data drawn from the subgroup of 74 patients with a chemotherapy-free interval greater than 30 days (CTFI>30 days) with a response rate of 52.7% and a median response duration of 7.6 months. Among the study data within this subgroup, the overall survival (OS) data is also encouraging, with a median of 12.7 months. The safety profile has proven to be manageable with a low percentage of treatment interruptions. Zepzelca® (lurbinectedin) is a synthetic compound derived from the tunicate Ecteinascidia turbinata found by PharmaMar in the Caribbean Sea, the Gulf of Mexico and the Mediterranean Sea. It is approved in 16 territories around the world. It received FDA accelerated approval in 2020 and has become the standard of care for second-line treatment in the United States. Confirmatory trials are currently underway, which may eventually lead to approval in Europe as well. One of the confirmatory studies, LAGOON, consists of three arms, one of which is lurbinectedin with irinotecan. The results presented at ASCO reinforce the rationale for including this combination as an experimental arm with this type of patient in this ongoing pivotal trial.お知らせ • Jun 02Pharma Mar, S.A., Annual General Meeting, May 31, 2023Pharma Mar, S.A., Annual General Meeting, May 31, 2023, at 11:30 Central European Standard Time. Location: The Auditorio Municipal Villa de Colmenar Viejo calle Molino de Viento, s/n, 28770 Colmenar Viejo Madrid Spain Agenda: To review and, as the case may be, approve the Annual Financial Statements and Management Reports of Pharma Mar, S.A. and of its Consolidated Group for the fiscal year ended December 31, 2022; to re-elect of the Statutory Auditors of the Company and its Consolidated Group; to consider Ratification, appointment and re-election of members of the Board of Directors; to consider Amendment of article 3 of Chapter I (Incorporation of the Company) of the Company's Bylaws; to authorize the Board of Directors, with express power of substitution, to buyback treasury stock, by the Company and/or by its subsidiary companies, under the terms provided by current legislation, with express power to proceed its transfer or amortization with reduction of the share capital number, leaving without effect, in the amount not used, the delegation agreed by the General Shareholders' Meeting of previous year; and to consider other matters.Reported Earnings • Mar 03Full year 2022 earnings released: EPS: €2.73 (vs €5.14 in FY 2021)Full year 2022 results: EPS: €2.73 (down from €5.14 in FY 2021). Revenue: €196.3m (down 15% from FY 2021). Net income: €49.4m (down 47% from FY 2021). Profit margin: 25% (down from 40% in FY 2021). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Global Biotechs industry.お知らせ • Dec 22Pharma Mar, S.A.(BME:PHM) dropped from Madrid Ibex 35 IndexPharma Mar, S.A. has been removed from Madrid Ibex 35 Index .Board Change • Nov 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Rosa Maria Alonso was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Board Change • Aug 01High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Independent Director Rosa Maria Alonso was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jul 29Pharma Mar, S.A. to Report Q2, 2022 Results on Jul 27, 2022Pharma Mar, S.A. announced that they will report Q2, 2022 results on Jul 27, 2022Reported Earnings • Jul 28Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €48.2m (up 1.7% from 2Q 2021). Net income: €12.9m (down 32% from 2Q 2021). Profit margin: 27% (down from 40% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is expected to shrink by 3.6% compared to a 214% growth forecast for the industry in Mexico.Board Change • Jul 18High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Independent Director Rosa Maria Alonso was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Upcoming Dividend • Jul 06Upcoming dividend of €0.53 per shareEligible shareholders must have bought the stock before 13 July 2022. Payment date: 15 July 2022. Payout ratio is a comfortable 13% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of Mexican dividend payers (6.1%). Lower than average of industry peers (2.4%).決済の安定と成長配当データの取得安定した配当: 配当金の支払いは安定していますが、 PHM1 Nが配当金を支払っている期間は 10 年未満です。増加する配当: PHM1 Nの配当金は増加していますが、同社は3年間しか配当金を支払っていません。配当利回り対市場Pharma Mar 配当利回り対市場PHM1 N 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (PHM1 N)2.0%市場下位25% (MX)0%市場トップ25% (MX)0%業界平均 (Biotechs)0%アナリスト予想 (PHM1 N) (最長3年)2.0%注目すべき配当: PHM1 Nの配当金 ( 1.96% ) はMX市場の配当金支払者の下位 25% ( 2.29% ) と比べると目立ったものではありません。高配当: PHM1 Nの配当金 ( 1.96% ) はMX市場の配当金支払者の上位 25% ( 5.95% ) と比較すると低いです。株主への利益配当収益カバレッジ: PHM1 Nは低い 配当性向 ( 23.8% ) であるため、配当金の支払いは利益によって十分にカバーされます。株主配当金キャッシュフローカバレッジ: PHM1 Nの 現金配当性向 ( 39.9% ) は比較的低く、配当金の支払いはキャッシュフローによって十分にカバーされています。高配当企業の発掘7D1Y7D1Y7D1YMX 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/06/12 01:21終値2023/03/16 00:00収益2023/03/31年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pharma Mar, S.A. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。12 アナリスト機関Jaime EscribanoBanco SantanderPatricia CifuentesBestinver Sociedad De Valores, S.AKambiz YazdiBTIG9 その他のアナリストを表示
Upcoming Dividend • Jul 06Upcoming dividend of €0.53 per shareEligible shareholders must have bought the stock before 13 July 2022. Payment date: 15 July 2022. Payout ratio is a comfortable 13% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of Mexican dividend payers (6.1%). Lower than average of industry peers (2.4%).
お知らせ • Feb 10Pharma Mar, S.A. to Report Fiscal Year 2024 Results on Feb 28, 2025Pharma Mar, S.A. announced that they will report fiscal year 2024 results on Feb 28, 2025
お知らせ • Oct 22Pharma Mar, S.A. to Report Q3, 2024 Results on Oct 29, 2024Pharma Mar, S.A. announced that they will report Q3, 2024 results on Oct 29, 2024
お知らせ • Oct 16Pharmamar Announces Positive and Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung CancerPharmaMar announced positive top-line results from the Phase 3 clinical trial evaluating Zepzelca® (lurbinectedin) in combination with the PD-L1 inhibitor atezolizumab (Tecentriq®) compared to atezolizumab alone when administered as a maintenance treatment for adults with extensive-stage Small Cell Lung Cancer (ES-SCLC) following induction therapy with carboplatin, etoposide and atezolizumab. The combination of lurbinectedin and atezolizumab demonstrated a statistically significant improvement in the primary endpoints of overall survival (OS) and progression-free survival (PFS), as assessed by an independent review facility (IRF), compared to treatment with atezolizumab alone. The combination was generally well-tolerated. The preliminary safety data in the ongoing trial is consistent with the known safety profiles of lurbinectedin and atezolizumab with no new safety signals observed in the combination arm. Jazz and Roche plan to submit these data for presentation at a future medical meeting. PharmaMar will submit a marketing authorisation application (MAA) to the EMA in the first half of 2025 to request regulatory approval in the European Union (EU). Lurbinectedin is available for use in 16 territories around the world.
お知らせ • Jul 27Pharma Mar, S.A. to Report First Half, 2024 Results on Jul 30, 2024Pharma Mar, S.A. announced that they will report first half, 2024 results on Jul 30, 2024
お知らせ • Jun 05Pharma Mar Presents Encouraging Results At ASCO for Small Cell Lung CancerPharmaMar presented data from a Phase II trial evaluating PharmaMar's lurbinectedin in combination with irinotecan in patients with relapsed Small Cell Lung Cancer (SCLC) after prior platinum-based treatment at the American Society of Clinical Oncology (ASCO) meeting, which took place from 31st May to 4th June in Chicago, United States. PharmaMar has a unique technological platform: the sea. Since 1986, it has been researching the marine ecosystem to discover innovative therapeutic alternatives for serious diseases, such as cancer, for this purpose it has invested more than EUR 1 billion since its foundation. After reaching patients all over the world and changing the paradigm of sarcoma treatment, in addition to having three therapies commercially available, it is currently working to improve the lives of patients with Small Cell Lung Cancer, the most aggressive type of lung cancer. Regarding this disease, the results presented by the company at ASCO show that the combination of its drug for this pathology, Zepzelca® (lurbinectedin), in combination with irinotecan produces a synergy that enhances the activity of lurbinectedin, resulting in high and durable response rates in populations that are sensitive, with a chemotherapy-free interval greater than 90 days (CTFI> 90 days), and platinum-resistant with a chemotherapy-free interval of less than 90 days (CTF< 90 days). Particularly encouraging are the data drawn from the subgroup of 74 patients with a chemotherapy-free interval greater than 30 days (CTFI>30 days) with a response rate of 52.7% and a median response duration of 7.6 months. Among the study data within this subgroup, the overall survival (OS) data is also encouraging, with a median of 12.7 months. The safety profile has proven to be manageable with a low percentage of treatment interruptions. Zepzelca® (lurbinectedin) is a synthetic compound derived from the tunicate Ecteinascidia turbinata found by PharmaMar in the Caribbean Sea, the Gulf of Mexico and the Mediterranean Sea. It is approved in 16 territories around the world. It received FDA accelerated approval in 2020 and has become the standard of care for second-line treatment in the United States. Confirmatory trials are currently underway, which may eventually lead to approval in Europe as well. One of the confirmatory studies, LAGOON, consists of three arms, one of which is lurbinectedin with irinotecan. The results presented at ASCO reinforce the rationale for including this combination as an experimental arm with this type of patient in this ongoing pivotal trial.
お知らせ • Jun 02Pharma Mar, S.A., Annual General Meeting, May 31, 2023Pharma Mar, S.A., Annual General Meeting, May 31, 2023, at 11:30 Central European Standard Time. Location: The Auditorio Municipal Villa de Colmenar Viejo calle Molino de Viento, s/n, 28770 Colmenar Viejo Madrid Spain Agenda: To review and, as the case may be, approve the Annual Financial Statements and Management Reports of Pharma Mar, S.A. and of its Consolidated Group for the fiscal year ended December 31, 2022; to re-elect of the Statutory Auditors of the Company and its Consolidated Group; to consider Ratification, appointment and re-election of members of the Board of Directors; to consider Amendment of article 3 of Chapter I (Incorporation of the Company) of the Company's Bylaws; to authorize the Board of Directors, with express power of substitution, to buyback treasury stock, by the Company and/or by its subsidiary companies, under the terms provided by current legislation, with express power to proceed its transfer or amortization with reduction of the share capital number, leaving without effect, in the amount not used, the delegation agreed by the General Shareholders' Meeting of previous year; and to consider other matters.
Reported Earnings • Mar 03Full year 2022 earnings released: EPS: €2.73 (vs €5.14 in FY 2021)Full year 2022 results: EPS: €2.73 (down from €5.14 in FY 2021). Revenue: €196.3m (down 15% from FY 2021). Net income: €49.4m (down 47% from FY 2021). Profit margin: 25% (down from 40% in FY 2021). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Global Biotechs industry.
お知らせ • Dec 22Pharma Mar, S.A.(BME:PHM) dropped from Madrid Ibex 35 IndexPharma Mar, S.A. has been removed from Madrid Ibex 35 Index .
Board Change • Nov 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Rosa Maria Alonso was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Board Change • Aug 01High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Independent Director Rosa Maria Alonso was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jul 29Pharma Mar, S.A. to Report Q2, 2022 Results on Jul 27, 2022Pharma Mar, S.A. announced that they will report Q2, 2022 results on Jul 27, 2022
Reported Earnings • Jul 28Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €48.2m (up 1.7% from 2Q 2021). Net income: €12.9m (down 32% from 2Q 2021). Profit margin: 27% (down from 40% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is expected to shrink by 3.6% compared to a 214% growth forecast for the industry in Mexico.
Board Change • Jul 18High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Independent Director Rosa Maria Alonso was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Upcoming Dividend • Jul 06Upcoming dividend of €0.53 per shareEligible shareholders must have bought the stock before 13 July 2022. Payment date: 15 July 2022. Payout ratio is a comfortable 13% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of Mexican dividend payers (6.1%). Lower than average of industry peers (2.4%).